<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03513016</url>
  </required_header>
  <id_info>
    <org_study_id>UBX0101-OAR-101</org_study_id>
    <nct_id>NCT03513016</nct_id>
  </id_info>
  <brief_title>A Safety and Tolerability Study of UBX0101 in Patients With Osteoarthritis of the Knee</brief_title>
  <official_title>A Phase 1, Double-Blind, Randomized, Placebo Controlled, Single Ascending Dose Study to Assess the Safety and Tolerability of UBX0101 in Moderate to Severe, Painful Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unity Biotechnology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Unity Biotechnology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate safety, tolerability, and pharmacokinetics of a single intra-articular&#xD;
      injection of UBX0101 in patients diagnosed with painful osteoarthritis of the knee.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a phase 1, randomized, double-blind, placebo-controlled single ascending dose&#xD;
      study that will evaluate safety, tolerability, and pharmacokinetics of UBX0101 in patients&#xD;
      diagnosed with painful femoro-tibial osteoarthritis. The study consists of 2 parts: Part A is&#xD;
      a single ascending dose study, whereas Part B is a single-dose study at a dose that has been&#xD;
      determined to be safe and tolerable in Part A of the study.&#xD;
&#xD;
      In Part A, subjects will be randomly allocated to receive UBX0101 or placebo in 3:1&#xD;
      randomization by dose level (cohort), whereas in Part B subjects will be randomly allocated&#xD;
      to receive UBX0101 or placebo in a 2:1 randomization.&#xD;
&#xD;
      The primary objective is to establish the safety and tolerability of UBX0101 given as a&#xD;
      single intra-articular injection into the femoro-tibial joint of patients with&#xD;
      osteoarthritis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 16, 2018</start_date>
  <completion_date type="Actual">April 12, 2019</completion_date>
  <primary_completion_date type="Actual">March 29, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of a single intra articular injection of UBX0101 evaluated by the incidence of serious and non-serious adverse events</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: Plasma concentration of UBX0101 over 24 hrs following a single intra-articular injection</measure>
    <time_frame>24 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: The change from baseline to Week 12 of the weekly mean of the average daily pain intensity score as obtained using the 11-point numerical rating scale [0-10] where 0 represents no pain and 10 represents worst pain imaginable</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: The change from baseline to Week 12 for the Western Ontario and McMaster Universities (WOMAC) index total score and the pain and function subscales using the 5-point Likert scale</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: The change from baseline to Week 4 of selected senescence-associated secretory phenotype factors in plasma samples and in synovial fluid aspirates in patients receiving a single intra-articular injection of UBX0101 versus those receiving placebo.</measure>
    <time_frame>Baseline to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: The change from baseline to Week 4 for the Western Ontario and McMaster Universities (WOMAC) index pain subscale using as derived from Knee injury and Osteoarthritis Outcome Score (KOOS).</measure>
    <time_frame>Baseline to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Plasma concentration of UBX0101 following a single intra-articular injection</measure>
    <time_frame>24 hrs</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Part A: UBX0101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: UBX0101, single intra-articular injection, ascending dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part A: Placebo, single intra-articular injection, ascending dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: UBX0101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B: UBX0101, single intra-articular injection, fixed dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part B: Placebo, single intra-articular injection, fixed dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UBX0101</intervention_name>
    <description>Investigational drug intra-articular injection</description>
    <arm_group_label>Part A: UBX0101</arm_group_label>
    <arm_group_label>Part B: UBX0101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Diluent intra-articular injection</description>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_label>Part B: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have the capacity to give informed consent and who are willing to comply&#xD;
             with all study related procedures and assessments. Patients who do not have the legal&#xD;
             capacity or medical competency to give written informed consent are not eligible for&#xD;
             this study; consent via legally authorized representative will not be accepted&#xD;
&#xD;
          -  Patients must be ≥ 40 and ≤ 85 years of age&#xD;
&#xD;
          -  Patients using non-steroidal anti-inflammatory agent must be on a consistent regimen,&#xD;
             dose, and medication for at least 8 weeks prior to enrollment&#xD;
&#xD;
          -  Part A only: Ambulatory persons with osteoarthritis (OA) of the knee and baseline pain&#xD;
             with a mean of ≥ 4 and ≤ 9 points on the 24-hour mean pain score (on the 11-point&#xD;
             Numeric Rating Scale) for at least five of the seven days during the screening period.&#xD;
&#xD;
          -  Part B only: Ambulatory persons with painful osteoarthritis (OA) of the knee for at&#xD;
             least six months.&#xD;
&#xD;
          -  Part B only: Patients with OA must have Kellgren-Lawrence scores 1 through 4 in the&#xD;
             target knee&#xD;
&#xD;
          -  Part B only: Patients must have a baseline pain ≥6 on the WOMAC Index pain subscale as&#xD;
             derived from the KOOS.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any condition, including laboratory findings and findings in the medical history or in&#xD;
             the pre-study assessments, that in the opinion of the Investigator constitutes a risk&#xD;
             or contraindication for participation in the study or that could interfere with the&#xD;
             study objectives, conduct or evaluation or prevent the Patient from fully&#xD;
             participating in all aspects of the study&#xD;
&#xD;
          -  Patients with clinically significant co-existing conditions of the cardiovascular,&#xD;
             renal, gastrointestinal, respiratory, nervous, metabolic, or hematologic/ immune&#xD;
             systems&#xD;
&#xD;
          -  Patients with a history of diabetes mellitus according to the American Diabetes&#xD;
             Association criteria or patients previously diagnosed by a qualified physician as&#xD;
             having diabetes (American Diabetes Association Standards of Medical Care in Diabetes&#xD;
             2016)&#xD;
&#xD;
          -  Patients with a history of cardiac rhythm disturbances, abnormal ECG intervals, or use&#xD;
             of medications known to impact ECG intervals&#xD;
&#xD;
          -  Patients who have undergone diagnostic arthroscopy of the Target Knee in the previous&#xD;
             six months&#xD;
&#xD;
          -  Patients who have undergone arthroscopic surgery in the last two years prior to the&#xD;
             screening visit (including microfracture and menisectomy) on the Target Knee.&#xD;
&#xD;
          -  Patients anticipated to have arthroscopic surgery on either knee at any time during&#xD;
             the study period&#xD;
&#xD;
          -  History of previous total or partial knee arthroplasty in either knee&#xD;
&#xD;
          -  Part A only: Patients with an effusion at the screening visit which, in the opinion of&#xD;
             the investigator following examination and discussions with the Patient, requires&#xD;
             drainage for symptom relief&#xD;
&#xD;
          -  Patients who have received intra-articular treatment with steroids or hyaluronic acid&#xD;
             derivatives within the last 16 weeks prior to screening&#xD;
&#xD;
          -  Patients who use, or have used in the 8 weeks prior to screening, opioid analgesics&#xD;
             (with exception of mild opioid analgesics)&#xD;
&#xD;
          -  Patients who have had regenerative joint procedures on any joint including, but not&#xD;
             limited to, platelet-rich plasma injections, mesenchymal stem cell transplantation,&#xD;
             autologous chondrocyte transplantation, or mosaicplasty&#xD;
&#xD;
          -  Current or history of other joint diseases such as joint dysplasia, crystal-induced&#xD;
             arthropathy (such as gout, or calcium pyrophosphate deposition disease evidenced by&#xD;
             clinical and/or radiographic means), aseptic osteonecrosis, acromegaly, Paget's&#xD;
             disease, Ehlers-Danlos Syndrome, Gaucher's disease, Stickler's syndrome, joint&#xD;
             infection, hemophilia, hemochromatosis, or neuropathic arthropathy of any cause&#xD;
&#xD;
          -  Any active known or suspected systemic autoimmune disease (except for vitiligo,&#xD;
             residual auto-immune hypothyroidism only requiring hormone replacement, psoriasis not&#xD;
             requiring systemic treatment for two years, conditions not expected to recur in the&#xD;
             absence of an external trigger) or any history of a systemic inflammatory arthritis&#xD;
             such as psoriatic, rheumatoid, ankylosing spondylitis or reactive arthritis&#xD;
&#xD;
          -  Patients diagnosed presently and symptomatic with fibromyalgia based on American&#xD;
             College of Radiology (ACR) Criteria&#xD;
&#xD;
          -  Patients with a BMI ≥ 40 kg/m2, or whose size exceed the limits of the of the MRI&#xD;
             equipment (coil and gantry)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jamie Dananberg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UNITY Biotechnology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TriWest Research Associates</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <zip>92020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioSolutions Clinical Research Center</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Well Pharma Medical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Pharmaceutical Research</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consortium</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metroplex Clinical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 27, 2018</study_first_submitted>
  <study_first_submitted_qc>April 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2018</study_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Painful Osteoarthritis</keyword>
  <keyword>Osteoarthritis, Knee</keyword>
  <keyword>Senescence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

